top of page

Mwandishi:

Mhariri:

ULY CLINIC

Dkt. Benjamin L, MD

16 Machi 2021 16:07:09

Metoclopramide na ujauzito

Metoclopramide na ujauzito

Taarifa mbalimbali za tafiti kuhusu matumizi ya metoclopramide kipindi cha kwanza cha ujauzito zimekuwa zikipingana hata hivyo metroclopramide imeendelea kutumika kwenye vipindi vyote vitatu vya ujauzito kama dawa ya kuzuia kichefuchefu na kutapika.


Licha ya tafiti nyingi za sasa na zamani kuonyesha kuwa dawa hii haina madhara katika uumbaji wa mtoto ikitumika katika kipindi cha kwanza cha ujauzito, kumekuwa na taarifa mpya kutoka kwenye tafiti chache zinazoonyesha kuwa matumizi ya metoclopramide katika kuzuia kichefuchefu kipindi hiki huongeza hatari ya watoto kuzaliwa na ulemavu wa viungo mbalimbali vya mwili.


Tafiti moja iliyofuatiliwa wajawazito 985 kwa muda wa miaka 17 toka mwaka 1998 hadi mwaka 2015, ilionyesha kuwa matumizi ya metroclopramide huhusiana na ulemavu mkuu kwa vichanga ikitumika miezi mitatu ya kwanza(kipindi cha kwanza cha ujauzito) ambapo uumbaji wa viungo vya kichanga hutoke.


Tafiti nyingine kubwa pia iliyofanyika kuanzia mwaka 1997 hadi mwaka 2011 ilionyesha majibu mengine. Kati ya wanjawazito 28 486 waliotumia metoclopramide katika kipindi cha kwanza cha ujauzito, wajawazito 721 walipata watoto wenye ulemavu mkuu, sawa na watoto 25.3 kwa kila watu 1000. Na wajawazito 3024 watoto wao walipata ulemavu mkuu kati ya wanawake 113 698 ambao hawakutumia dawa hii sawa na watoto 26.6 kuzaliwa na ulemavu kwa kila wajawazito 1000 waliotumia dawa. Utafiti hii uliohusisha wajawazito wengi zaidi unahitimisha kuwa, hakuna mahusiano makubwa kati ya matumizi ya metroclopramide na kupata watoto wenye ulemavu mkuu wa kuzaliwa.


Hitimisho


Licha ya kutokuwa na ushahidi wa kutosha kuhusu matumizi ya metroclopramide na madhaifu ya kuzaliwa, ifahamike kuwa matumizi ya dawa yoyote ile huwa na madhara kwa kichanga na mama haswa katika kipindi cha kwanza cha ujauzito. Mtumiaji wa dawa sikuzote anapaswa kupima faida anazopata dhidi ya madhara yanayoweza kujitokeza kwake na mtoto tumboni au kutumia dawa ambazo zimethibitishwa kutosababisha kabisha ulemavu kwa kichanga.


Ushauri dhidi ya matumizi kwa mama mjamzito


Inapatana na ujauzito


Inapatana na ujauzito ina maana gani?

Uzoefu wa matumizi ya metroclopramide kwa wajawazito au dawa zingine zilizo kundi moja au zenye kufanya kazi kwa utaratibu unaofanana, zimetosha kuonyesha kuwa, madhara kwa kichanga tumboni ni madogo sana au hakuna madhara kabisa. Tafiti za uzazi kwa wanyama kuhusu dawa hii hazina uhalisia kwa binadamu.


Ushauri wa matumizi kwa mama anayenyonyesha


Hakuna ( zipo taarfa chache) taarifa kwa wajawazito, hivyo inaweza kuwa sumu kwenye ukuaji wa kichanga


Hakuna ( zipo taarifa chache) taarifa kwa binadamu- inaweza kuwa sumu kwenye ukuaji wa kichanga ina maana gani?

Inaweza kuwa taarifa juu ya matumizi ya metroclopramide kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii hazipo au zipo chache. Sifa za ufanyaji kazi wa dawa zinaonyesha kuwa dawa hii inaweza kuwa sumu kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii. Hivyo hairuhusiwi kumnyonyesha mtoto unapotumia metroclopramide.



ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha  vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.

Imeboreshwa,

1 Julai 2023 17:21:36

Rejea za mada hii

1. Pasternak B, Svanström H, Mølgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in Pregnancy and Risk of Major Congenital Malformations and Fetal Death. JAMA. 2013;310(15):1601–1611. doi:10.1001/jama.2013.278343

2. Li Sun,Yang Xi, et al. Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis. https://doi.org/10.1371/journal.pone.0257584. Imechukuliwa 20.04.2022

3. Anick Bérard, et al. New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. Inapatikana kwenye linki https://doi.org/10.1016/j.jclinepi.2019.07.014. Imechukuliwa 20.04.2022

4. Bylsma-Howell M, et al. Placental transport of metoclopramide: assessment of maternal and neonatal effects. Can Anaesth Soc J 1983;30:487–92.

5. Arvela P, et al. Placental transfer and hormonal effects of metoclopramide. Eur J Clin Pharmacol 1983;24:345–8.

6. Cohen SE, et al. Does metoclopramide decrease the volume of gastric contents in patients undergoing cesarean section? Anesthesiology 1984;61:604–7.

7. Lyonnet R, Lucchini G. Metoclopramide in obstetrics. J Med Chir Prat 1967;138:352–5.

8. Sidhu MS, Lean TH. The use of metoclopramide (Maxolon) in hyperemesis gravidarum. Proc Obset Gynaecol Soc Singapore 1970;1:1–4.

9. Guikontes E, Spantideas A, Diakakis J. Ondansetron and hyperemesis gravidarum. Lancet 1992;340:1223.

10. Martynshin MYA, et al. Experience in treating early toxicoses of pregnancy with metoclopramide. Akush Ginekol 1981;57:44–5.

11. Pinder RM, et al. Metoclopramide: a review of its pharmacological properties and clinical use. Drugs 1976;12:81–131.

12. Harrington RA, et al. Metoclopramide: an update review of its pharmacological properties and clinical use. Drugs 1983;25:451–94.

13. McGarry JM. A double-blind comparison of the anti-emetic effect during labour of metoclopramide and perphenazine. Br J Anaesth 1971;43:613–5.

14. Howard FA, Sharp DS. Effect of metoclopramide on gastric emptying during labour. Br Med J 1973;1:446–8.

15. Brock-Utne JG, et al. The effect of metoclopramide on the lower oesophageal sphincter in late pregnancy. Anaesth Intensive Care 1978;6:26–9.

16. Hey VMF, Ostick DG. Metoclopramide and the gastro-oesophageal sphincter. Anaesthesia1978;33:462–5.

17. Feeney JG. Heartburn in pregnancy. Br Med J 1982;284:1138–9.

18. Murphy DF, et al. Effect of metoclopramide on gastric emptying before elective and emergency caesarean section. Br J Anaesth 1984;56:1113–6.

19. Vella L, Francis D, Houlton P, Reynolds F. Comparison of the antiemetics metoclopramide and promethazine in labour. Br Med J 1985;290:1173–5.

20. Messinis IE et al. Effect of metoclopramide on maternal and fetal prolactin secretion during labor. Obstet Gynecol 1982;60:686–8.

21. Bohnet HG, Kato K. Prolactin secretion during pregnancy and puerperium: response to metoclopramide and interactions with placental hormones. Obstet Gynecol 1985;65:789–92.

22. Roti E, et al. Failure of metoclopramide to affect thyrotropin concentration in the term human fetus. J Clin Endocrinol Metab 1983;56:1071–5.

23. Milo R, et al. Acute intermittent porphyria in pregnancy. Obstet Gynecol 1989;73:450–2.

24. Nageotte MP, et al. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. Am J Obstet Gynecol 1996;174:1801–6.

25. Turcotte V, et al. Utilité du dropéridol et de la diphenhydramine dans l’hyperemesis gravidarum. J Soc Obstet Gynaecol Can 2001;23:133–9.

26. Sorensen HT, et al. Birth outcome following maternal use of metoclopramide. Br J Clin Pharmacol 2000;49:264–8.

27. Berkovitch M, et al. Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. N Engl J Med 2000;343:445–6.

28. Product information. Reglan. A.H. Robins, 1997.

29. Eisenach JC, Dewan DM. Metoclopramide exaggerates stress-induced tachycardia in pregnant sheep. Anesth Analg 1996;82:607–11.

30. Shenhav S, et al. Acute intermittent porphyria precipitated by hyperemesis and metoclopramide treatment in pregnancy. Acta Obstet Gynecol Scand 1997;76:484–5.

31. Orr DA, et al. Effects of omeprazole, with and without metoclopramide, in elective obstetric anaesthesia. Anaesthesia 1993;48:114–9.

32. Stuart JC, et al. Acid aspiration prophylaxis for emergency caesarean section. Anaesthesia 1996;51:415–21.

33. Robuschi G, et al. Failure of metoclopramide to release GH in pregnant women. Horm Metab Res 1983;15:460–1.

34. Lewis PJ, Devenish C, Kahn C. Controlled trial of metoclopramide in the initiation of breast feeding. Br J Clin Pharmacol 1980;9:217, 219.

35. Pelkonen O, et al. Metoclopramide in breast milk and newborn (abstract). Acta Physiol Scand 1982;(Suppl 502):62.

36. Kauppila A, et al. Metoclopramide and breast feeding: transfer into milk and the newborn. Eur J Clin Pharmacol 1983;25:819–23.

37. Sousa PLR. Metoclopramide and breast-feeding. Br Med J 1975;1:512.

38. Guzman V, et al. Improvement of defective lactation by using oral metoclopramide. Acta Obstet Gynecol Scand 1979;58:53–5.

39. Kauppila A, et al. Metoclopramide increases prolactin release and milk secretion in puerperium without stimulating the secretion of thyrotropin and thyroid hormones. J Clin Endocrinol Metab 1981; 52:436–9.

40. Kauppila A, et al. A dose response relation between improved lactation and metoclopramide. Lancet 1981;1:1175–7.
41. de Gezelle H, et al. Metoclopramide and breast milk. Eur J Obstet Gynecol Reprod Biol 1983;15:31–6.

42. Kauppila A, et al. Metoclopramide and breast feeding: efficacy and anterior pituitary responses of the mother and the child. Eur J Obstet Gynecol Reprod Biol 1985;19:19–22.

43. Gupta AP, Gupta PK. Metoclopramide as a lactogogue. Clin Pediatr 1985;24:269–72.

44. Ehrenkranz RA, Ackerman BA. Metoclopramide effect on faltering milk production by mothers of premature infants. Pediatrics 1986;78:614–20.

45. Budd SC, et al. Improved lactation with metoclopramide. Clin Pediatr 1993;32:53–7.

46. Toppare MF, et al. Metoclopramide for breast milk production. Nutrition Research 1994;14:1019–29.

47. Sankaran K, et al. Use of metoclopramide in preterm infants. Dev Pharmacol Ther 1982;5:114–9.

48. Lewis JH, Weingold AB, The Committee on FDA-Related Matters, American College of Gastroenterology. The use of gastrointestinal drugs during pregnancy and lactation. Am J Gastroenterol 1985;80:912–23.

49. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776–89.

bottom of page